D-150 continues to be well tolerated with no intraocular inflammation observed at any timepoint or dose level4D-150 demonstrated durable and dose-dependent clinical activity with sustained gains in ...

The big opening pop is the latest indication that the tech IPO market has reopened following a multiyear lull that began in ...

OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical innovation approaches to health and ...